AUG 0 6 2001

Form PTO-1449

Department of Commerce Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No. Serial No. 55669-A-PCT-US 09/753,169

Applicant

Cy A. Stein

Filing Date 01/02/01

Group 1635

## U.S. PATENT DOCUMENTS

	I	Doc	ume	∍nt	Nu	mbe	;r	Date	Name	Class	Subclass	Filing Date
AA	5	0	2	3	2	4	3	6/11/91	Tullis, R.			if Appropriate
AB	5	1	0	7	0	6	5			<del> </del>		
AC	5	4	9	6	5	4						
AD	5	5	8	7	4	7	0			1		
ΑE	5	5	9	3	9	7		1				+
AF	5	6	7	0	6	3	3	I T			+	<del></del>
AG	5	6	8	9	0	5						<del></del>
АН	5	7	0	2	8	9	7					+
AI	5	7	3	4	0	3	3			+		
AJ .	5	7	7	6	9	0	T = T					<del>]</del>
AK	5	8	4	3	7	1	3					
	AB AC AD AE AF AG AH AI AJ	AA 5 AB 5 AD 5 AE 5 AF 5 AH 5 AH 5 AJ 5	AA 5 0 AB 5 1 AC 5 4 AD 5 5 AE 5 6 AF 5 6 AH 5 7 AI 5 7 AI 5 7	AA     5     0     2       AB     5     1     0       AC     5     4     9       AD     5     5     8       AE     5     5     9       AF     5     6     7       AG     5     6     8       AH     5     7     0       AJ     5     7     3       AJ     5     7     7	AA     5     0     2     3       AB     5     1     0     7       AC     5     4     9     6       AD     5     5     8     7       AE     5     5     9     3       AF     5     6     7     0       AG     5     6     8     9       AH     5     7     0     2       AI     5     7     3     4       AJ     5     7     7     6	AA     5     0     2     3     2       AB     5     1     0     7     0       AC     5     4     9     6     5       AD     5     5     8     7     4       AE     5     5     9     3     9       AF     5     6     7     0     6       AG     5     6     8     9     0       AH     5     7     0     2     8       AI     5     7     3     4     0       AJ     5     7     7     6     9	AA     5     0     2     3     2     4       AB     5     1     0     7     0     6       AC     5     4     9     6     5     4       AD     5     5     8     7     4     7       AE     5     5     9     3     9     7       AF     5     6     7     0     6     3       AH     5     7     0     2     8     9       AI     5     7     3     4     0     3       AJ     5     7     7     6     9     0	AA       5       0       2       3       2       4       3         AB       5       1       0       7       0       6       5         AC       5       4       9       6       5       4       7       0         AD       5       5       8       7       4       7       0         AE       5       6       7       0       6       3       3         AG       5       6       8       9       0       5       2         AH       5       7       0       2       8       9       7         AI       5       7       3       4       0       3       3         AJ       5       7       6       9       0       5       6	AA 5 0 2 3 2 4 3 6/11/91 AB 5 1 0 7 0 6 5 4/21/92 AC 5 4 9 6 5 4 7 3/96 AD 5 5 8 7 4 7 0 12/24/96 AE 5 5 9 3 9 7 4 1/97 AF 5 6 7 0 6 3 3 8/23/97 AG 5 6 8 9 0 5 2 11/97 AH 5 7 0 2 8 9 7 12/97 AI 5 7 3 4 0 3 3 3/31/98 AJ 5 7 7 6 9 0 5 7/98	AA 5 0 2 3 2 4 3 6/11/91 Tullis, R.  AB 5 1 0 7 0 6 5 4/21/92 Schewmaker, et al.  AC 5 4 9 6 5 4 7 3/96 Lam et al.  AD 5 5 8 7 4 7 0 12/24/96 Cook et al.  AE 5 5 9 3 9 7 4 1/97 Rosenberg et al.  AF 5 6 7 0 6 3 3 8/23/97 Cook et al.  AB 5 7 0 2 8 9 7 12/97 Brown et al.  AI 5 7 3 4 0 3 3 3/31/98 Reed et al.  AJ 5 7 7 6 9 0 5 7/98 Gibbons et al.	AA 5 0 2 3 2 4 3 6/11/91 Tullis, R.  AB 5 1 0 7 0 6 5 4/21/92 Schewmaker, et al.  AC 5 4 9 6 5 4 7 3/96 Lam et al.  AD 5 5 8 7 4 7 0 12/24/96 Cook et al.  AE 5 5 9 3 9 7 4 1/97 Rosenberg et al.  AF 5 6 7 0 6 3 3 8/23/97 Cook et al.  AB 5 7 0 2 8 9 7 12/97 Reed et al.  AI 5 7 3 4 0 3 3 3/31/98 Reed et al.  AJ 5 7 7 6 9 0 5 7/98 Gibbons et al.	AA 5 0 2 3 2 4 3 6/11/91 Tullis, R.  AB 5 1 0 7 0 6 5 4/21/92 Schewmaker, et al.  AC 5 4 9 6 5 4 7 3/96 Lam et al.  AD 5 5 8 7 4 7 0 12/24/96 Cook et al.  AE 5 5 9 3 9 7 4 1/97 Rosenberg et al.  AF 5 6 7 0 6 3 3 8/23/97 Cook et al.  AB 5 7 0 2 8 9 7 12/97 Reed et al.  AI 5 7 3 4 0 3 3 3/31/98 Reed et al.  AJ 5 7 7 6 9 0 5 7/98 Gibbons et al.

## FOREIGN PATENT DOCUMENTS

Country Class	Date	Date	Document Number								
WO	./98 WO	02/9	7	7	7	5	0	8	9	AL	1/2
WO	/95 WO	06/9	0	0	4	5	1	5	9	AM	1/1
			Ш	L				_			10
		<u> </u>									

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Agrawal, S., et al., Proc. Natl. Acad. Sci. U.S.A. (1988) Vol. 85:7079-7083;

Antisense'97: A roundtable on the state of the industry. Nature Biotechnology 15 (June 1997): 519-524;

Beaucage, S., and Caruthers, M., Tetrahedron Lett. (1981) Vol. 22:1859-1862;

EXAMINER/

DATE CONSIDERED

6-12-02

\*EXAMINEK: Initia of reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.



INFORMATION DISCLOSURE STATEMENT

U.S. Department of Commerce Form PTO-1449 Patent and Trademark Office

Atty. Docket No. 55669-

Serial No. 09/753,169

A-PCT-US

Applicant

	(Use several sheets if necessary)	Applicant Cy A. Steir	1
		Filing Date 01/02/01	Group /435
OTHER	DOCUMENTS (Including Author, Title, Date, F	ertinent Pa	ges, Etc.)
	Cook, P.D., "Medicinal Chemistry of Antise	nse Oligonuo	cleotides
1/2	- future opportunities" (1991) Anti Cancer	Drug Desigr	n Vol. 6:585:
	-607;		
<del>                                     </del>			
	Crooke, S.T. VitraveneAnother piece in t	he Mosaic.	Antisense and
	Nucleic Acid Drug Dev. 8(1998):vii-viii.		
	Cowrite of all Engilitation		
	Gewritz et al. Facilitating oligonucleotid	e delivery:	Helping
	antisense deliver on it s promise. Proc. N (April 1996); 3161-3163.	atl. Acad. S	Sci. USA 93
	(April 1990); 3161-3163.		
	Ghosh, S. et al. J. Riol Chom. (1999) v	-1 055	
	Ghosh, S., et al., J. Biol. Chem. (1990) V	01. 265:2935	5-2940
1	Gura, T. Antisense has growing pains. Scien	270 (0~+	1005) 555
	577	ice 270 (Oct	. 1995): 5/5-
	Hemken, P., et al., J. Biol. Chem. (1992)	Vol. 267.994	8-0057.
			.0 0037,
\	Iverson, P., Anti-Cancer Drug Des. (1991)	Vol. 6:531-5	38:
\	Krajewska, M. et al. "Immunohistochemical a	nalysis bcl	-2, bax,
	bcl-x, and mcl-1 expression in prostate car	ncer." Am. J	. Pathol.
	(1996) Vol. 148:1567-1576;		
	Luedeke, G.H., Ziegler, Al., Stahel, R.A.,	and Zangeme	ister-Wittke,
12	U., "Antisense oligonucleotides targeting s	equences sha	ared by the
(K)	Bcl-2 and the Bcl-xL mRNA efficiently downr	egulate exp	ression of
XAMINER /	both proteins and induce apoptosis of lung	cancer cell	s." Division
XAMINER //	DAME CONGENERS		

EXAMINER

DATE CONSIDERED

\*EXAMINER Initial of reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant.

Form PTO-	Patent and Trademark Office	Atty. Docket No. 55669- A-PCT-US	Serial No. 09/753,169								
	INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Cy A. Stein	n								
		Filing Date 01/02/01	Group /635								
OTHER	DOCUMENTS (Including Author, Title, Date,		ges, Etc.)								
	of Oncology, Department of Internal Medic	cine, Univers	ity Hospital								
19	CH-8091 Zurich, Switzerland. (Abstract #1140 from 88 Ann. Meet.										
	AACR, April 12-16, 1997, Vol. 38, (March	1997), p. 17	1);								
	Milligan et al., "Current Concepts in Ant	isense Drug I	Design" Journ								
	of Medicinal Chemistry (July 9, 1993) Vol	l. 36:1924-19	37;								
	Pollman et al., "Inhibition of neointimal	cell bcl-x e	expression								
	induces apoptosis and regression of vascu	ılar disease.	'Nature								
	Medicine (1998) Vol. 4:222-227;										
1	Ratajczak, et al., Proc. Natl. Acad. Sci.	U.S.A. (199	2) Vol.								
	89:11823;										
	Rojanasakul, Y. Antisense oligonucleotide	therapeutics	s: Drug								
	delivery and targeting. Adv. Drug delive										
	Stein, C.A. Keeping the biotechnology of	antisense in	context.								
	Nature Biotechnology 17 (March 1999):209										
	Stull et al. Antigene, ribozyme and aptam	ner nucleic ad	cid drugs:								
	Progress and prosepcts. Pharm. Res. 12 (A	pril 1995): 4	65-483.								
	Uhlmann, E. And Peyman A., "Antisense Oli										
	Therapeutic Principle" Chem. Rev. (1990)										
	Wang, Z. et al., "Induction of bcl-xl by	CD40 Engageme	nt Rescues								
1/4	slg-induced Apoptosis in Murine B Cells",	The Journal	of Immunolog								
y/V	(1995) Vol. 155:3722-3725;										
	T GAS Ford DATE CONSIDERED 6-12-03										
AMINER! Initia	reference considered, whether or not citation is in conformance were and not considered. Include copy of this from with next communication	ith MPEP 609; Draw li	ne through citation								

Sheet 4 of 4 Form PTO-1449 . Department of Commerce Patent and Trademark Office Atty. Docket Serial No. No. 55669-09/753,169 INFORMATION DISCLOSURE STATEMENT A-PCT-US (Use several sheets if necessary) Applicant Cy A. Stein Filing Date OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Zhao, Q., et al., Antisense Research and Development (1993) Vol. Zon, G., "Oligonucleotide Analogues as Potential Chemotherapeutic Agents," Pharmaceutical Research (November 9, 1988) Vol. 5:539-549;

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this from with next communication to applicant

AUG 0 6 2001

EXAMINER